Global Facioscapulohumeral Muscular Dystrophy Market, By Type (Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2), Treatment (Medication, Physical Therapy, Others), Diagnosis (Blood Tests, Magnetic Resonance Imaging (MRI), Electromyography (EMG), Genetic Testing, DNA Mutation Analysis, Others), Symptoms (Muscle Weakness, Mild High-Tone Hearing Loss, Difficulty Whistling, Abnormalities, Atrophy, Lordosis, Others), Dosage (Injection, Tablets, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Analysis and Insights Global Facioscapulohumeral Muscular Dystrophy Market
Facioscapulohumeral muscular dystrophy market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 4% in the above mentioned forecast period.
Facioscapulohumeral muscular dystrophy (FSHD) is a rare genetic muscle illness that most commonly affects the muscles of the face, upper arms and shoulder blades. Muscular dystrophy is a progressive muscle degeneration disorder characterised by increased muscle weakness and atrophy (muscle loss of mass). The face, shoulders, and upper arms are the first and most severely affected muscles in FSHD, but other muscles are generally affected as well. FSHD is caused by mutations in various genes (mutations). In most cells in the body, a gene called DUX4 is inactive, but in FSHD, it becomes active. In FSHD type-2, which is less frequent, other genetic variables play a role. Both types produce problems in the same way. Both boys and girls are affected by FSHD. It can be passed down to their children by either parent. This is a pattern of autosomal dominant inheritance. Each kid of a parent who carries the FSHD gene has a one-in-two chance of inheriting it.
The rise in the number of patients suffering from facioscapulohumeral muscular dystrophy will act as major driver that will results in the expansion of market’s growth. Another significant factor influencing the growth rate of facioscapulohumeral muscular dystrophy market is the rising healthcare expenditure. Furthermore, advancement in the medical technology, growing government funding and rising initiatives by public and private organisations to spread awareness about genetic disorders are the factors that will expand the facioscapulohumeral muscular dystrophy market. Other factors such as increasing adoption of early genetic counseling and favourable reimbursement policies will positively impact the facioscapulohumeral muscular dystrophy market’s growth rate. Additionally, high demand for effective treatment options and novel therapies will result in the expansion of facioscapulohumeral muscular dystrophy market.
Moreover, the rise in the research and development activities and launch of effective therapies will provide beneficial opportunities for the facioscapulohumeral muscular dystrophy market in the forecast period of 2022-2029. Also, ongoing clinical trials and strategic collaborations of leading manufacturers will escalate the growth rate facioscapulohumeral muscular dystrophy market in future.
However, high cost associated with the symptomatic treatment and lack of infrastructure in low-income countries will impede the growth rate of facioscapulohumeral muscular dystrophy market. Additionally, complications involved with facioscapulohumeral muscular dystrophy will hinder the facioscapulohumeral muscular dystrophy market growth. Less awareness about facioscapulohumeral muscular dystrophy and the lack of cure for this disease will further challenge the market in the forecast period mentioned above.
This facioscapulohumeral muscular dystrophy market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the facioscapulohumeral muscular dystrophy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Facioscapulohumeral Muscular Dystrophy Market Scope and Market Size
The facioscapulohumeral muscular dystrophy market is segmented on the basis of type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of type, the facioscapulohumeral muscular dystrophy market is segmented into facioscapulohumeral muscular dystrophy 1 and facioscapulohumeral muscular dystrophy 2.
- On the basis of treatment, the facioscapulohumeral muscular dystrophy market is segmented into medication, physical therapy and others. The medication segment is further sub-segmented into non-steroidal anti-inflammatory drugs (NSAID) and others.
- On the basis of diagnosis, the facioscapulohumeral muscular dystrophy market is segmented into blood tests, magnetic resonance imaging (MRI), electromyography (EMG), genetic testing, DNA mutation analysis and others.
- On the basis of symptoms, the facioscapulohumeral muscular dystrophy market is segmented into muscle weakness, mild high-tone hearing loss, difficulty whistling, abnormalities, atrophy, lordosis and others.
- On the basis of dosage, the facioscapulohumeral muscular dystrophy market is segmented into injection, tablets and others.
- On the basis of route of administration, the facioscapulohumeral muscular dystrophy market is segmented into oral, parenteral and others.
- On the basis of end-users, the facioscapulohumeral muscular dystrophy market is segmented into clinic, hospital and others.
The facioscapulohumeral muscular dystrophy market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Facioscapulohumeral Muscular Dystrophy Market Country Level Analysis
Facioscapulohumeral muscular dystrophy market is analyzed and market size information is provided by the country, type, treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the facioscapulohumeral muscular dystrophy market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the facioscapulohumeral muscular dystrophy market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing patient pool, rising investment in the healthcare sector, and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Facioscapulohumeral muscular dystrophy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Facioscapulohumeral Muscular Dystrophy Market Share Analysis
Facioscapulohumeral muscular dystrophy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to facioscapulohumeral muscular dystrophy market research.
Some of the major players operating in the facioscapulohumeral muscular dystrophy market are Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Sanofi, Abbott, Bayer AG, Johnson & Johnson Private Limited, Boehringer Ingelheim International GmbH, AstraZeneca, Assertio Holdings, Inc., Horizon Therapeutics plc, Perrigo Company plc, F. Hoffmann-La Roche Ltd., Mylan N.V., Allergan, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Lupin, AbbVie Inc., Eli Lilly and Company, and Cipla Inc., among others.
Recent Development
In May 2021, Fulcrum Therapeutics, Inc., has announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation to losmapimod for the potential treatment of Facioscapulohumeral muscular dystrophy (FSHD). There are presently no approved treatments for FSHD, and losmapimod is the sole medication in clinical research for this significant and debilitating condition. Losmapimod is developed to accommodate the unmet medical needs of individuals with FSHD.
SKU-